The efficacy of concurrent chemoradiotherapy for patients with inoperable esophageal cancer

Results : The overall response rate was 89%. The median overall survival was 24.7 months, the 1-year and 3-year overall survival rate was 71% and 32%, respectively. The 1-year and 3-year progression-free survival rate was 86% and 54%, respectively. Grade 3/4 hematological toxicities included neutropenia in 50% of the patients, anemia in 25%, and thrombocytopenia in 14%. Grade 3 and 4 non-hematological toxicities were less common. Conclusions : These results suggest that concurrent chemoradiotherapy is an effective regimen.(Korean J Med 72:37-43, 2007)